Oteseconazole: First Approval

Drugs. 2022 Jun;82(9):1017-1023. doi: 10.1007/s40265-022-01734-y.

Abstract

Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections. It inhibits cytochrome P450 (CYP) 51, thereby affecting the formation and integrity of the fungal cell membrane, but has a low affinity for human CYP enzymes due to its tetrazole metal-binding group. Oteseconazole is the first agent to be approved (in April 2022) for recurrent vulvovaginal candidiasis (RVVC) in the USA, where it is indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential. Clinical development for the treatment of onychomycosis, and invasive and opportunistic infections is ongoing. This article summarizes the milestones in the development of oteseconazole leading to this first approval for reducing the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential.

Publication types

  • Review

MeSH terms

  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Azoles / pharmacology
  • Azoles / therapeutic use
  • Candidiasis, Vulvovaginal* / drug therapy
  • Candidiasis, Vulvovaginal* / epidemiology
  • Candidiasis, Vulvovaginal* / microbiology
  • Female
  • Humans
  • Incidence
  • Recurrence

Substances

  • Antifungal Agents
  • Azoles